Emcure Arm Acquires UK-Based Manx’s Portfolio For ₹2.19 Billion

Emcure Pharmaceuticals Ltd.’s subsidiary Tillomed Laboratories Ltd. has entered into an asset purchase agreement with UK-based Manx Healthcare Ltd. and its subsidiaries Manx Pharma Ltd. and Manx Generics Ltd. to acquire their product portfolio for £19.7 million, or about ₹2.19 billion. The deal includes relevant dossiers, marketing authorisations, intellectual property, and inventory worth £4.7 million.

Of the total consideration, £6.2 million will be paid upfront, with the remaining amount staggered over 18 months based on agreed milestones, the company said in an exchange filing on Friday.

Emcure said the deal will strengthen its product offering and deepen its market presence. “Through the acquisition of Manx’s established and high-quality products portfolio, we reinforce our commitment to delivering accessible healthcare solutions,” it said.